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:ةصلاخلا 
: فدهلا  ًَاثنا عىُنا ٍي يزكسنا ىظزي حعىًدي ٍٍت ٍٍغناثهن زوذحنا زخأرًنا ًذاذنا ًعاًُنا يزكسنا راشرَا ذٌذحذ ىه حسارذنا فذه
.اٌزٌزس ٍٍصخشًنا 
 : ةيجهنملا  مٍدسذ ىذ082 ٍي ىهعًٍدذ ىذ ذمنو حسارذنا ِذه ًف ًَاثنا عىُنا ٍي يزكس طٌزي  ٍٍسحنا ىفشي ًف يزكسنا حٌراشرسا
 واعهن ٌازٌزح ٍي جزرفهن ءلاتزك ًف ًًٍهعرنا0212  ًناحنا واعنا ٍي ًَاثنا ٌىَاك حٌاغنو0212  واهفرسلاا ًف حٍنارنا خايىهعًنا دًُظ ذمنو
ثل وذنا ًف زكسنا مٍهحذ,جلاعنا عىَ,يزكسنا عىَ,ًهئاعنا خٌرارنا,حٍصخشنا خايىهعًنا:طٌزي مكن يزٌزسنا ٍٍٍتىهكىًٍهنا,راطفلإا م
 ًذاذنا ًعاًُنا يزكسنا حثسَ باسرحات اٍئاصحإ دههح حئارُنا .يزكسنا ةثست حهصاحنا خافعاعًناو ضزًنا جذي,ىسدنا حهرك زشؤي,يزكسنا
   .ياك عتزي راثرخاو ًَاثنا عىُنا ٍي يزكسنا ىظزي ذُع ٍٍغناثهن زوذحنا زخأرًنا 
: حئاتنلا نا ًعاًُنا يزكسنا راشرَا ل اٌواسي ٌاك ًَاثنا عىُنا ٍي يزكسنا ىظزي ذُع ٍٍغناثهن زوذحنا زخأرًنا ًذاذ1 .10 ىنإ حفاظإ .:
زكسنا ضزي جزرفو ىسدنا حهرك زشؤي,يزكسنا ٍٍٍتىهكىًٍهنا,راطفلإا مثل وذنا ًف زكسنا مٍهحذ, ,ًهئاعنا خٌرارنا ًف يىُعي قزف دىخو 
 : جاتنتسلااًنا يزكسنا راشرَا وا حثسَ زٌذمذ طٌزًنا زًعو حٍحصنا اهعلاو ٍي زٍثكت ملا ًه اٌزٌزس ٍٍغناثهن زوذحنا زخأرًنا ًذاذنا ًعاُ
 .يزكسنا عاىَأ ٍٍت كٌزفرهن حهٍسىك ذًرعٌلا ٌأ ةدٌ 
 : تايصىتلا.يزكسنات حتاصلإا حٌاذت ًف ىظزًنا مك ذُع ٍٍنىسَلأن حٍذاذنا خاداعًنا مٍهحذ داًرعا 
Abstract: 
Objective: the aim of the study is to determine the prevalence of LADA among group of clinically 
diagnosed type 0 diabetes mellitus. 
Methodology: sample size equal to 082 patients with type 0 D.M. were subjected in this study, 
participating patients were consecutively recruited from Diabetes outpatient clinic in AL-Hussein Teaching 
Hospital in Karbala from June, 0212 through January, 0212. A clinical questioner containing personal data, 
family history, type of diabetes, type of treatment, FBS, HA1C, BMI, diabetes duration& complications of 
diabetes. For analysis of data Prevalence of LADA among D.M.0 cases was calculated as the proportion of 
LADA cases in the D.M.0 cases. The Chi square test (X0) was used to assess the significance (P-value) of 
differences in frequencies of categorical variables.  
Results: prevalence of LADA among D.M.0 patients was 10.1:. A significant difference in family history, 
BMI, FBS, HA1C and duration of D.M was found between the studied groups. 
Conclusion: The prevalence of LADA is clinically underestimated among D.M0 patients and 
age of onset of diabetes should no longer be considered as a valid way to differentiate diabetes.  
Recommendation: the study recommends screening for islet cell autoantibodies as GAD56 for all patients 
with diabetes at onset or beginning of disease. 
Key word: GAD65, LADA, diabetes mellitus. 
INTRODUCTION 
     Diabetes mellitus is a group of metabolic diseases in which a patient has increase 
blood sugar, because the pancreas does not secret enough insulin, or unresponsiveness of 
cells to the insulin that is produced 
(1)
.  Diabetes mellitus is categorized into general 
categories: type1, type0, gestational diabetes and other specific types. The specific types 
are group of a few dozen individual causes 
(1)
.Type 0 diabetes is characterized by 
impaired β-cell function and may be accompanied with changes of the immune system (0). 
Latent autoimmune diabetes in adults (LADA) or Type 1.6 diabetes has some clinical 
features of type 0 diabetes & shows immunological abnormalities similar to those in type 
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1 diabetes, such as glutamic acid decarboxylase antibody (GADA) (2).So far it is not 
understood why disease progression in LADA is slower than in type 1 diabetes despite the 
immunological similarities. Insulin secretion was reported to be intermediate in LADA 
compared with type 1 and type 0 diabetes, whereas metabolic syndrome was similar in 
type 1 diabetes and LADA (2).  
     Type 1.6 diabetes is usually diagnosed after the age of 26 years and there is no 
immediate requirment for insulin therapy (6).  Approximately 12: to 22: of adults with 
type 0 diabetes test positive for autoantibodies, depending on the age and ethnicity of the 
study group (5). The immune-mediated destruction of beta-cells in type 1.6 diabetics leads 
to insulin dependency more rapidly than in type 0 diabetes, but the more attenuated 
genetic and immune factors associated with type 1.6 diabetes as compared with type 1 
diabetes lead to an older age at onset and a slower progression to insulin dependency 
(7).The Clinical characteristics predictive of type 1.6 diabetes include: Age < 62 years, 
acute symptoms of hyperglycemia (polydypsia, polyuria, or unintentional weight loss), 
body mass index < 06 kg per m , family history of autoimmune disease (thyroid disorders, 
celiac disease, type 1 diabetes, rheumatoid arthritis or any other form autoimmune 
disorder), personal history of autoimmune disease (thyroid disorders, celiac disease, type 
1 diabetes, rheumatoid arthritis or any other form of autoimmune disorder). The presence 
of at least two of these clinical features (LADA risk score ≥ 0) was found to have 92 % 
sensitivity and 71 % specificity for identifying diabetic patients affected by type 1.6 
diabetes. Patients with one or no feature were unlikely to have LADA (8). 
Type 1.6 diabetes and type 0 diabetes populations can be distinguished from each 
other based on clinical features, but a large degree of overlap exists between the two types 
of diabetes. Hence, the use of immunogenetic markers, in particular the measurement of 
autoantibodies, remains the gold standard for identifying type 1.6 diabetic patients. 
Identification of these patients is clinically relevant to their management as the early use 
of insulin resulted in β-cell preservation in several pilot studies (9). Type 1.6 diabetes is 
diagnosed by the presence of pancreatic auto-antibodies, such as glutamic acid 
decarboxylase (GAD) antibodies in an adult initially presenting with non-insulin 
dependent diabetes (12). 
PATIENTS AND METHOD 
A 082 individual were enrolled in this study at the period from June, 0212 through 
January, 0212. All patients were selected randomly from Diabetes outpatient clinic in AL-
Hussein Teaching Hospital in Karbala; these patients were clinically diagnosed as type 0 
D.M, 126 males &126 females with age range from 22-72 years, and duration of disease 
between 1 month -06 years. Descriptive variables of patients included:   name, age, 
gender, type of diabetes, type of treatment (insulin, OHD, diet or mixed), FBS, HA1C, 
BMI, complications they were suffered due to D.M. and duration of disease. Serum 
samples were taken from all patients and subjected to ELISA analysis by GAD56 ELISA 
kits (CUSABIO BIOTECH CO., LTD. USA) which is a solid phase enzyme 
immunoassay based on the sandwich technique, in which two monoclonal antibodies are 
directed against separated antigenic determinants on the GAD56 molecule.                                                                                                                                                                                                        
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RESULTS 
 
Figure1. Prevalence of LADA among 581 D.M.5 cases 
Figure 1 shows that out of the 082 patients with type II D.M., 22 had LADA, 
GAD56 positive this giving a prevalence of LADA among D.M.0 patients equal to 
(10.1:). 
Table1. Comparison of baseline characteristics of LADA and DM5 cases 
Variable 
DM5   No.=546 LADA  No.=44 
Statistics 
No. % No. % 
Age (years) 
≤  41 41 1664 1 567 
X
5
= 968 
P= 1611 
NS 
41 – 41 44 1967 4 868 
41 – 51 51 5164 8 5465 
51-61 95 5765 15 4461 
> 61 41 1664 9 5166 
Gender 
Male 155 5168 14 4165 X
5
= 1696 
P= 1648 
NS Female 151 4765 51 5868 
Family 
history 
Positive 511 8568 51 6168 X
5
= 1165 
P= 16111 
Sig Negative 45 1465 14 4865 
BMI 
(kg/m
5
) 
Normal (18 - 5467) 54 764 11 4564 X
5
= 1467 
P=  < 
16111 
Sig 
Overweight (55 - 5767) 197 9568 18 5567 
Obese (>=41) 44 1967 5 1469 
FBS 
(mg/dl) 
Mean ± SD 565 ± 81 518 997 
16111 
Sig 
HA1C (%) Mean ± SD 764 ± 164 864 ± 165 
< 16111 
Sig 
Duration 
of DM 
(years) 
< 5 54 5167 16 4961 X
5
= 1964 
P=  < 
16111 
sig 
 
5 – 7 47 1567 5 1469 
11 – 14 151 4868 5 1469 
≥15 44 1464 8 5465 
Mean ± SD 1164 ± 465 761 ± 564  
Type of 
treatment 
With Insulin 54 5165 8 5465 X
5
=164  
P= 1661 
NS Without Insulin 174 9865 51 6168 
Complicati
ons 
Positive 74 4865 9 5166 X5= 464 
P= 1619 Negative 155 6168 59 9764 
87.9% 
12.1% 
DM2
LADA
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NS 
The comparison of baseline characteristics of studied groups as it shown in table 1 
revealed: 
A significant differences in family history (P=2.221); Positive family history was 
more frequent in D.M.0 than LADA cases; 011 (86.6:) vs. 01 (51.8:), respectively. 
A highly significant difference in BMI; D.M.0 cases were more likely to be 
overweight and obese than LADA cases, (P<2.221). 
A highly significant difference in mean FBS and HA1C, D.M.0 cases had higher 
mean FBS (056 ± 82) mg/dl higher mean HA1C (9.2: ± 1.2:) than LADA cases (the 
mean FBS was 018879, and the mean HA1C was (8.2: ± 1.0:) 
Duration of D.M. was highly significant longer in D.M.0 group than LADA group, 
(P<2.221). 
No significant differences had been found in age, gender, type of treatment or 
complications in between both groups, in all comparison , P>2.26. 
 
Figure5. Comparison of mean BMI values of studied group 
The mean BMI of D.M.0 group was 07.88 2.5 kg/m0, of LADA group was 06.782.6, it 
had been significantly found that patients in D.M.0 group had the higher BMI value than 
LADA. 
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Figure4. Proportional distribution of complications in DM5 and LADA groups 
LADA cases have 17.7: retinopathy and 0.9: diabetic foot. 
DISCUSSION 
     LADA is not a rare disease, and many subjects are still under diagnosed. Without 
awareness, a correct diagnosis of LADA is not easy. Adults with LADA may initially be 
diagnosed as having type 0 diabetes based on their age, particularly if they have risk 
factors for type 0 diabetes such as a strong family history or are obese.82: of persons 
initially diagnosed with type 0 but test positive for GAD  progress to insulin dependency 
within 5 years (some sources say between 2–10 years after diagnosis) (11).  
     Our study shows that from the 082 diabetic patients, there were (22) GADA 
positive, the prevalence of LADA was 10.1:. This result is in line with what was 
obtained by Olufunmilayo study (10) who report prevalence rate equal to 12:, also reports 
from Ghana where documented prevalence rates for LADA amongst people being 
managed for type 0 DM was 12.6: (12) and the study of Lutale et al., showed a level of 
islet cell positivity 7.2: (12). However other studies done in Korea found lower prevalence 
rate of LADA 2.2: (16) & 2.7: (15). Seissler and Scherbaum demonstrated the relative high 
frequency of this form of diabetes (approximately 02:) among type 0 diabetic patients in 
the age range 06-22 years. This difference could be attributed to the difference in 
population ethnicity and age of onset of the disease (17). 
     Regarding demographic characteristics of the studied groups, although no 
significant difference in age between LADA & D.M.0 Majority of the subjects with 
LADA in this study were in 21–62, 61-52 & ˃52 age categories (22/22 cases) and less 
than 11.7: were in other age categories. This observation suggests that LADA increases 
with increasing age decade, confirming result observed by Olufunmilayo study (10) & 
Carlson et al. study (18) that older age was an important risk factor for LADA as for Type 0 
DM and this may suggest a potential role for insulin resistance in the pathogenesis of 
LADA. Similarly Chinese study found that the prevalence of LADA slowly increased 
with age up to 52 years and was high in individuals aged 62–69 years (19). 
     Our study shows that the presence of LADA is non sex specific although the higher 
percentage (68.8:) of patients positive for antiGAD autoantibodies in this study were 
13.9% 
5.6% 5.6% 
2.8% 2.8% 
17.7% 
2.9% 
0.0% 0.0% 0.0% 
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females, this may be due to the fact that autoimmune diseases are more common in 
females than males and the logical cause for this difference would be the sex hormones, 
females might respond more to conventional antigens due to sex hormones. This goes 
with other studies as Olufunmilayo study who found (52:) of subjects positive for 
antiGAD autoantibodies were females (10) & same result was clarified by Qi et al. (19).  
     A highly significant difference in BMI between LADA & D.M.0 cases; D.M.0 
cases were more likely to be overweight and obese than LADA cases this is due to insulin 
resistant in those patients. This finding is similar to what was obtained by Genovese et al. 
as they concluded that, LADA patients are non obese in contrast to those who are actually 
type 0 DM as they are mostly obese with BMI >22 (02). Although 60.9: of LADA patients 
are overweight in our study, this may be due to the fact that they have low levels of 
insulin & improper treatment with oral hypoglycemic drugs. The proportion of 
overweight among subjects with LADA in this study was higher than those in normal 
weight category and this suggests insulin resistance as possible contributory factor in the 
pathogenesis of LADA amongst our patients. The mean BMI of our study LADA patients 
was 06.7 kg/m , which is lower than that of Western studies (07.6 to 20 kg/m ), (01) . This 
result is in agreement with report done by Yul Hwangbo in Korea that found mean BMI 
was 06.2 kg/m  (16) and this may be explained due to different features related to different 
ethnic groups. 
     Significant positive family history for D.M.0(86.8:), although high percent of 
LADA (51.8:) have positive family history for type 0 D.M., Olufunmilayo study reveal 
that 29: of LADA patients have positive family history for type 0 D.M. (10). 
     Duration of diabetes was highly significant longer in GAD negative than LADA 
group; this goes with studies done in Korea & Nigeria where longer duration of disease 
reported in D.M.0 (16; 10).  
Regarding insulin treatment 02.6: of LADA patients were already on insulin at the 
time of the study for glycaemic control, although statistically result is not significant. 
Other studies found that 16:, 27: of LADA cases were on insulin treatment at study time 
(16; 10) respectively, and this may be due to autoimmune destruction of the β-cells which 
has been reported to be present at diagnosis of diabetes in LADA patients (5).  
     A higher proportion of subjects with LADA had evidence of microvascular 
complications of diabetes namely retinopathy while D.M.0 cases had more macrovascular 
complications. The foregoing would suggest that macrovascular complications were more 
frequent in D.M.0 patients, while LADA subjects manifest predominantly microvascular 
complications especially retinopathy. The poor indices of long term glycemic control in 
LADA may account for the observed higher percentage of LADA subjects with evidence 
of microvascular DM complications. This is in agreement with finding of study from 
Turkey (00), Reports from Western Finland (19) & study of Olufunmilayo (10).  
     A highly significant difference in mean FBS and HA1C, D.M.0 cases had higher 
mean FBS (056 ± 82) mg/dl & higher mean HA1C (9.2: ± 1.2:) than LADA cases, 
although LADA cases still have high level of FBS & HA1C (the mean FBS was 018879, 
and the mean HA1C was (8.2: ± 1.0:).This result is similar to Olufunmilayo study who 
revealed mean HA1C equal to 8.281.8 in LADA patients (10). In Yul Hwangbo report 
HA1C mean was 880.2 for LADA cases versus 7.681.5 for D.M.0 cases, FBS mean 
127.2822.1 for LADA versus 126.8821.2 for D.M.0 cases (16), these differences in results 
in comparison to our study may be due to different patient’s education, dietary habits & 
self care. 
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CONCLUSION: 
1. The prevalence of LADA is clinically underreported among D.M0 patients 
and age of onset of diabetes should no longer be considered as a valid way to 
differentiate diabetes.  
0. Patients with LADA who are characterized by autoimmunity to pancreatic 
beta cells show a clinical phenotypic with anthropometric features that are 
similar to type 1diabetic patients & differed from those clinically observed in 
patients with type 0 DM. 
2. LADA increases with increasing age decade. 
2. D.M.0 patients were more obese & overweight than LADA patients due to 
insulin resistant in those patients. 
RECOMMENDATION: 
1. Screening for islet cell autoantibodies should be done at onset of diabetes by 
simple & reliable test to confirm the autoimmune nature of disease. 
0. Type 0 diabetic patients with clinical criteria of LADA patients should be 
screened for GADA as they considered as marker for autoimmunity to 
confirm the diagnosis of autoimmune diabetes in those patients for 
appropriate diabetic management, to predict insulin dependency & to prevent 
future complications due to poor glycemic control.  
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